Pfizer reported Q3 adjusted EPS of $0.87 vs $0.73 expected (+19%) on revenue of $16.58B vs $15.85B expected; non-COVID revenue grew 7% and Eliquis sales jumped 25% to $2.52B. It raised full-year 2026 revenue guidance to $62-64B and adjusted EPS guidance to $2.95-3.05.
Useful?